Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004527184 | SCV005039840 | likely pathogenic | Friedreich ataxia 1 | 2024-03-18 | criteria provided, single submitter | clinical testing | Variant summary: FXN c.483-12_483del13 spans a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a 3' acceptor site. However, these predictions have yet to be confirmed by functional studies. The variant was absent in 250972 control chromosomes (gnomAD). To our knowledge, no occurrence of c.483-12_483del13 in individuals affected with Friedreich Ataxia and no experimental evidence demonstrating its impact on protein function have been reported. No submitters have cited clinical-significance assessments for this variant to ClinVar. Based on the evidence outlined above, the variant was classified as likely pathogenic. |